Spotlight on medicines: Dronedarone
Medicines used to treat atrial fibrillation can cause various side effects. Dronedarone, the most recent antiarrhythmic drug to become available, is well tolerated. This article looks at its place in therapy
Antiarrhythmic treatment options for patients with atrial fibrillation are limited and an antiarrhythmic drug that can control symptoms with improved tolerability over amiodarone is a welcome addition.
Dronedarone, however, has limited ability to cardiovert patients to sinus rhythm and should be reserved for the maintenance of sinus rhythm in patients who have previously been cardioverted and for the control of ventricular rate.
Because dronedarone is not proarrhythmic and it also lacks the non-cardiac side effects seen with other antiarrhythmics, it is an attractive second-line option in certain pre-specified patient groups.
Full text article available to read as a PDF (1.3 MB) file.
Gemma Robinson is specialist cardiac pharmacist and Sotiris Antoniou is principal cardiac pharmacist, both at Barts and The London NHS Trust.
Citation: Clinical Pharmacist URI: 11027205
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now